GlassScriptPhysician profile
Maurice E Varon
NPI 1396749974
$14,517.86
in general payments reported to CMS, 2019-2025
23 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $53.42 · 2021: $634 · 2022: $1,872 · 2023: $764 · 2024: $464 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,503.01 | 2019-2025 | Watchman, Watchman Flx |
| Edwards Lifesciences Corporation | $1,336.77 | 2020-2025 | |
| Amgen INC. | $372.03 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $359.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $347.49 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.30 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $206.38 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $196.14 | 2022-2025 | |
| Irhythm Technologies, INC. | $144.27 | 2021-2023 | Zio Xt Patch |
| Abbott Laboratories | $138.04 | 2022-2023 | Aveir |
| Scpharmaceuticals INC. | $117.76 | 2023 | |
| Sanofi-Aventis U.S. LLC | $96.23 | 2022-2023 | |
| Astellas Pharma US INC | $81.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.51 | 2020-2022 | |
| Biotronik INC. | $57.07 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.13 | 2022-2023 | Verquvo |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $33.03 | 2022-2024 | Camzyos |
| Impulse Dynamics (USA) INC. | $28.48 | 2024 | Optimizer |
| Cvrx, INC. | $22.16 | 2023 | Barostim Neo System |
| Bridgebio Pharma, INC. | $17.31 | 2025 | Attruby |
| Medtronic Vascular, INC. | $16.77 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Varon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.